Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $35.52 USD
Change Today +0.74 / 2.13%
Volume 60.8K
VASC On Other Exchanges
As of 5:20 PM 11/25/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

6464 Sycamore Court North

Minneapolis, MN 55369

United States

Phone: 763-656-4300

Fax: 877-656-4251

Vascular Solutions, Inc., a medical device company, provides various solutions to interventional cardiologists, interventional radiologists, electrophysiologists, and vein practices worldwide. Products and Services The company’s product and service offerings are divided into three categories: catheter products, hemostat products, and vein products and services. Catheter Products The company’s catheter products consist of various devices used to gain access, diagnose, and treat vascular conditions during minimally invasive catheterization procedures. The company’s main selling catheter product is the GuideLiner guide extension device. The company received CE Mark and launched GuideLiner in Europe in 2009, and received 510(k) clearance and launched GuideLiner in the U.S. in 2009. The GuideLiner catheter is a unique coaxial ‘mother-and-child’ guide extension device with rapid exchange convenience that enables deep seating, guide back-up support, and selective intubation in challenging coronary interventions. In 2011, the company launched the second generation of its GuideLiner catheter with increased flexibility, a smaller size version and a longer extension. In 2013, the company launched the third generation version, GuideLiner V3, which features a polymer ‘half-pipe’ collar to enhance stent and wire deployment. In 2013, its Japanese distributor received Shonin approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) to permit sales of the GuideLiner in Japan. The company’s Pronto catheters consist of a catheter with a proprietary distal tip and large extraction lumen that can be delivered into arteries to mechanically remove blood clots using simple vacuum suction. In addition to the Pronto V3 and V4, the company has developed and launched four additional versions of extraction catheters - the Pronto-Short, Pronto 035, Pronto LP and Pronto XL. The Pronto-Short is a shorter and larger version, designed for use in clotted dialysis grafts that was launched in 2005. The Pronto 035 is a larger version, designed for use in large vessels that was launched in 2007. The Pronto LP is a low profile version, designed for use in smaller vessels that was launched in 2008. The Pronto XL extraction catheter is an even larger version with either a straight or pigtail tip, designed for use in very large vessels that was launched in 2012. In 2003, the company launched various introducer products used to gain percutaneous access to the vasculature for performing arterial and venous catheterization procedures. These products include a full line of micro-introducer kits and various specialty guidewires. In 2004, the company received regulatory clearance in the United States for the Langston dual lumen pigtail catheter. The Langston catheter is used for the measurement of intravascular pressure gradients, primarily measured to diagnose aortic valve stenosis. In 2010, the company acquired the SmartNeedle doppler guided needle products from Escalon Vascular Access, Inc. The SmartNeedle products consist of a hand-held monitor and one-time use needles designed to provide auditory ultrasound guided access to arteries and veins during catheterization procedures. In 2012, the company acquired the Venture catheter from St. Jude Medical, and the company launched the Venture catheter in the U.S. and international markets in 2013. The Venture catheter features a tip that deflects up to 90 degrees for precise direction of 0.014’ guidewires through tortuous anatomy. During 2007, the company entered into an agreement with Zerusa Limited (Zerusa) to act as the exclusive U.S. distributor of Zerusa’s Guardian hemostatic valve. The Guardian hemostatic valve is a valve used in catheterization procedures to allow the placement of multiple devices simultaneously in the artery with a unique push-button operation that is designed to minimize blood loss. In 2009, the company began distribution of a second generation version called the Guardian II hemostatic valve. In 2011, the company acquired substantially all of the assets of Zerusa Limited, including the Guardian hemostasis valves and established a wholly-owne


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VASC:US $35.52 USD +0.74

VASC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AtriCure Inc $22.24 USD +0.59
Cardiovascular Systems Inc $16.55 USD +0.91
CryoLife Inc $11.00 USD +0.25
Endologix Inc $10.24 USD +0.25
Spectranetics Corp/The $13.51 USD -0.07
View Industry Companies

Industry Analysis


Industry Average

Valuation VASC Industry Range
Price/Earnings 47.9x
Price/Sales 4.2x
Price/Book 4.8x
Price/Cash Flow 41.1x
TEV/Sales 4.0x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact VASCULAR SOLUTIONS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at